文献速递肿瘤 PET/CT

前瞻性评估全身MRI与18F-FDG PET/MRI在初诊乳腺癌患者N分期和M分期中的价值

Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-04-24

本研究前瞻性纳入104例初诊经组织病理学证实的乳腺癌患者,分别评估全身MRI与全身18F-FDG PET/MRI对N分期和M分期的诊断效能。PET/MRI对恶性淋巴结的敏感性显著优于MRI(p=0.008),两者M分期正确率均为96.2%但各有4例假阳性,基于病灶分析PET/MRI判断恶性病灶的正确率显著更高且诊断信心更优。

要点

  • PET/MRI对恶性淋巴结的敏感性显著优于MRI(p=0.008)。
  • 两种方法M分期正确率均为96.2%,但各出现4例假阳性(3.8%)。
  • 基于病灶分析PET/MRI正确判断恶性病灶的比例显著高于MRI。

核心结论

  • 18F-FDG PET/MRI对初诊乳腺癌N分期的诊断准确性优于MRI,且在病灶定性方面诊断信心显著高于单独MRI。
  • 但两种方法均存在高估M分期的风险。

研究设计与样本

  • 前瞻性纳入104例初诊经组织病理学证实的乳腺癌患者(年龄53.4±12.5岁)。
  • 所有患者接受全身18F-FDG PET/MRI检查,MRI与PET/MRI数据集分别独立评估病灶计数、定位、定性(恶性/良性)及诊断信心(5分有序量表,1-5分)。
  • N分期和M分期依据美国癌症联合委员会第八版分期手册分别基于单独MRI和PET/MRI数据集评定。
  • 多数病灶以组织病理学为参考标准,其余病灶通过影像学和临床检查随访。
  • 分别对淋巴结阳性和阴性女性采用McNemar卡方检验比较PET/MRI与MRI的N分期和M分期敏感性和特异性,诊断信心评分差异采用Wilcoxon符号秩检验。

主要发现

  • MRI正确判定N分期78/104例(75%),敏感性62.3%(95%CI:0.48-0.75),特异性88.2%(95%CI:0.76-0.96),PPV 84.6%(95%CI:69.5-0.94),NPV 69.2%(95%CI:0.57-0.8)。
  • 18F-FDG PET/MRI正确判定N分期87/104例(83.7%),敏感性75.5%(95%CI:0.62-0.86),特异性92.2%(95%CI:0.81-0.98),PPV 90%(95%CI:0.78-0.97),NPV 78.3%(95%CI:0.66-0.88),确定恶性淋巴结的敏感性显著优于MRI(p=0.008)。
  • MRI和18F-FDG PET/MRI正确判定M分期均为100/104例(96.2%),两者均正确分期全部7例远处转移患者,每种方法各出现4例假阳性(3.8%)。
  • 基于病灶分析,18F-FDG PET/MRI正确判定恶性病灶的比例为85.8%,MRI为67.1%,差异18.7%(95%CI:0.13-0.26),p<0.0001。
  • 18F-FDG PET/MRI诊断信心评分4.1±0.7,优于单独MRI的3.4±0.7(p<0.0001)。

关键数值与推荐

  • N分期和M分期依据美国癌症联合委员会第八版分期手册评定。
  • 诊断信心采用5分有序量表(1-5分)评估。
  • 多数病灶以组织病理学为参考标准,其余病灶通过影像学和临床检查随访。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate and compare the diagnostic potential of whole-body MRI and whole-body 18F-FDG PET/MRI for N and M staging in newly diagnosed, histopathologically proven breast cancer. MATERIAL AND METHODS: A total of 104 patients (age 53.4 ± 12.5) with newly diagnosed, histopathologically proven breast cancer were enrolled in this study prospectively. All patients underwent a whole-body 18F-FDG PET/MRI. MRI and 18F-FDG PET/MRI datasets were evaluated separately regarding lesion count, lesion localization, and lesion characterization (malignant/benign) as well as the diagnostic confidence (5-point ordinal scale, 1-5). The N and M stages were assessed according to the eighth edition of the American Joint Committee on Cancer staging manual in MRI datasets alone and in 18F-FDG PET/MRI datasets, respectively. In the majority of lesions histopathology served as the reference standard. The remaining lesions were followed-up by imaging and clinical examination. Separately for nodal-positive and nodal-negative women, a McNemar chi2 test was performed to compare sensitivity and specificity of the N and M stages between 18F-FDG PET/MRI and MRI. Differences in diagnostic confidence scores were assessed by Wilcoxon signed rank test. RESULTS: MRI determined the N stage correctly in 78 of 104 (75%) patients with a sensitivity of 62.3% (95% CI: 0.48-0.75), a specificity of 88.2% (95% CI: 0.76-0.96), a PPV (positive predictive value) of 84.6% % (95% CI: 69.5-0.94), and a NPV (negative predictive value) of 69.2% (95% CI: 0.57-0.8). Corresponding results for 18F-FDG PET/MRI were 87/104 (83.7%), 75.5% (95% CI: 0.62-0.86), 92.2% (0.81-0.98), 90% (0.78-0.97), and 78.3% (0.66-0.88), showing a significantly better sensitivity of 18F-FDG PET/MRI determining malignant lymph nodes (p = 0.008). The M stage was identified correctly in MRI and 18F-FDG PET/MRI in 100 of 104 patients (96.2%). Both modalities correctly staged all 7 patients with distant metastases, leading to false-positive findings in 4 patients in each modality (3.8%). In a lesion-based analysis, 18F-FDG PET/MRI showed a significantly better performance in correctly determining malignant lesions (85.8% vs. 67.1%, difference 18.7% (95% CI: 0.13-0.26), p < 0.0001) and offered a superior diagnostic confidence compared with MRI alone (4.1 ± 0.7 vs. 3.4 ± 0.7, p < 0.0001). CONCLUSION: 18F-FDG PET/MRI has a better diagnostic accuracy for N staging in primary breast cancer patients and provides a significantly higher diagnostic confidence in lesion characterization than MRI alone. But both modalities bear the risk to overestimate the M stage.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bruckmann NM, Sawicki LM, Kirchner J, et al. Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients. Eur J Nucl Med Mol Imaging. 2020. PMID: 32333068. doi:10.1007/s00259-020-04801-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。